Drug hunters hoping to prevent or delay the onset of Alzheimer’s disease take note—a new mouse model developed at RIKEN offers a powerful platform for evaluating potential therapies designed to combat the neurodegenerative disease in its earliest stages.
Alzheimer’s disease is globally the most common neurodegenerative disorder. Many compounds that showed promise in mice models of the disease subsequently flopped in clinical trials on people. One reason for…
